Subject(s)
Humans , Female , Pregnancy , Inflammatory Bowel Diseases/drug therapy , Biological TherapyABSTRACT
The prevalence of inflammatory bowel disease (IBD) increased in the last decades. Thus, the number of pregnant women with the condition is also increasing. Given that active disease itself is the main risk factor for complications during pregnancy, it is necessary to achieve a complete remission before planning a pregnancy. Also, pregnant women with IBD must be monitored noninvasively and be treated proactively, including escalated therapies, if needed, to prevent potential flares during pregnancy. Patients can undergo vaginal delivery in most forms of IBD. However, cesarean delivery is still preferable in women with a history of ileal pouch-anal anastomoses (IPAA) or active perianal disease.
Subject(s)
Female , Humans , Pregnancy , Pregnancy Complications , Inflammatory Bowel Diseases , Colitis, Ulcerative , Proctocolectomy, Restorative , Pregnancy Complications/epidemiology , Inflammatory Bowel Diseases/therapy , Inflammatory Bowel Diseases/epidemiology , Colitis, Ulcerative/surgery , Cesarean Section , Delivery, ObstetricABSTRACT
The management of Inflammatory Bowel Disease has progressed over the years largely due to better therapeutic options. These current management is guided by the primary goal in achieving clinical and endoscopic remission (deep remission), thus improving the quality of life of patients. In order to achieve these objectives however, there are risks associated which must always be considered. It is important to recognize that IBD patients are at risk of infection and neoplastic lesions for the natural history of the disease or the therapies that we used. Prevention of possible complications must be carried out. Options in therapeutic management not only include pharmacological therapy, but also include an adequate nutritional setting and an optimal correction of nutritional deficits. These alternative nutritional strategies can and should be considered as an effective therapeutic strategy aimed at improving the quality of life of IBD patients.
El manejo de la enfermedad inflamatoria intestinal ha progresado con el paso de los años dado a mayores opciones terapéuticas. El manejo actual se guía por objetivos para lograr remisión clínica y endoscópica (remisión profunda) mejorando así la calidad de vida de estos pacientes. Sin embargo, para lograr estos objetivos, se debe considerar siempre los riesgos asociados a las nuevas terapias. Es importante reconocer que los pacientes con EII son personas en riesgo tanto de infecciones como de lesiones neoplásicas por la historia natural de la enfermedad y/o por las terapias utilizadas, por lo tanto, la prevención de posibles complicaciones debe ser realizada en forma periódica. Por otro parte, el manejo terapéutico, no solo incluye la terapia farmacológica, sino también una adecuada optimización nutricional y una adecuada corrección de los déficit nutricionales secundarios. En este mismo sentido terapias alternativas, pueden ser consideradas como estrategia terapéuticas complementarias destinadas a mejorar la calidad de vida de estos pacientes.
Subject(s)
Humans , Inflammatory Bowel Diseases/prevention & control , Bone Diseases, Metabolic/etiology , Bone Diseases, Metabolic/prevention & control , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/therapy , Immunization , Diet Therapy , Secondary Prevention , Neoplasms/etiology , Neoplasms/prevention & controlABSTRACT
Intestinal parasitic infections cause a not insignificant number of chronic diarrhea in children, however, with the sociodemographic change that our country has experienced, the number of cases and new parasites (immigration from tropical endemic areas) could increase. We report the case of an immunocompetent patient who presents with chronic diarrhea associated with Strongyloides stercoralis infection. The patient migrated two years ago from an endemic area for this helminth. The diagnosis is challenging, and the chances of a successful outcome depend on the administration of the antiparasitic.
Las infecciones parasitarias intestinales provocan un número no despreciable de causas de diarrea crónica en niños, sin embargo, con el cambio sociodemográfico que ha vivido nuestro país se podría incrementar el número de casos y de nuevos parásitos (inmigración de áreas endémicas tropicales). Reportamos el caso de un paciente inmunocompetente, que presenta cuadro de diarrea crónica asociada a infección por Strongyloides stercoralis. El paciente habría migrado hace dos años desde zona endémica para este helminto. El diagnóstico es desafiante y las posibilidades de un resultado exitoso dependen de la administración del antiparasitario.
Subject(s)
Humans , Male , Adult , Strongyloidiasis/diagnosis , Strongyloidiasis/drug therapy , Intestinal Diseases, Parasitic/diagnosis , Intestinal Diseases, Parasitic/drug therapy , Strongyloidiasis/parasitology , Tomography, X-Ray Computed , Albendazole/therapeutic use , Strongyloides stercoralis/isolation & purification , Diarrhea/etiology , Immunocompetence , Intestinal Diseases, Parasitic/parasitologyABSTRACT
Biological therapies have been essential for the management of inflammatory bowel disease; however, their high cost results in many patients being unable to access them. With time, commercial patents of many "original" biologics are reaching or almost in the point of reaching the expiration date of their licenses, which has allowed for the development of new agents known as biosimilars leading to a reduction of the cost of these therapies. The objective of this review is to explain what biosimilars are and show evidence of their effectiveness and safety.
Las terapias biológicas son parte fundamental en el manejo de la enfermedad inflamatoria intestinal, sin embargo los costos de éstas han hecho que muchos de los pacientes que tienen indicación de su uso, no puedan utilizarlas. Con el paso del tiempo, muchos biológicos "originales" están alcanzando o a punto de alcanzar el vencimiento de sus patentes, lo que ha llevado al desarrollo de nuevos agentes conocidos como biosimilares, determinando una disminución en los costos de estas terapias. Esta revisión tiene como objetivo explicar en qué consisten los biosimilares y la evidencia actual con respecto a su eficacia y seguridad.
Subject(s)
Humans , Inflammatory Bowel Diseases/drug therapy , Biosimilar Pharmaceuticals/therapeutic use , Therapeutic Equivalency , Colitis, Ulcerative/drug therapy , Crohn Disease/drug therapy , Chile , Interchange of DrugsABSTRACT
The management of inflammatory bowel disease (IBD) is constantly changing due to the arrival of new therapeutic agents. Combined therapy (biological associated with immunosuppressive therapy) has proven to be effective, reducing immunogenicity (antibody formation), optimizing the pharmacokinetics of biological therapy with anti-TNF. This therapeutic strategy has associated risks (neoplasia and intercurrent infections) that are not only explained by the use of drugs but also by the increase of cases in older ages. It is essential for the medical team to be familiar with the optimization and personalization of the therapy to achieve clear therapeutic objectives with the lowest possible risks.
El manejo de la enfermedad inflamatoria intestinal (EII) está en constante cambio, debido a la llegada de nuevos agentes terapéuticos. La terapia combinada (terapia biológica asociada a inmunosupresores) ha demostrado ser efectiva al disminuir la inmunogenicidad (formación de anticuerpos) permitiendo la optimización farmacocinética. Esta estrategia terapéutica tiene riesgos asociados (neoplasias e infecciones intercurrentes) que no sólo se explican por el uso de fármacos sino también por el aumento de casos en edades más avanzadas. Es fundamental que el equipo tratante este familiarizado con la optimización y personalización de la terapia para así lograr objetivos terapéuticos claros con los menores riesgos posibles.
Subject(s)
Humans , Inflammatory Bowel Diseases/drug therapy , Tumor Necrosis Factors/antagonists & inhibitors , Immunologic Factors/therapeutic use , Immunosuppressive Agents/therapeutic use , Azathioprine/adverse effects , Azathioprine/therapeutic use , Biological Therapy/methods , Drug Therapy, Combination , Immunologic Factors/adverse effects , Immunosuppressive Agents/adverse effects , Antibodies, Monoclonal/therapeutic useABSTRACT
Background: In Chile, 80 diseases were included in a health care system called Health Care Guarantees (GES) and clinical guidelines were elaborated for their management. Aim: To assess the scientific background of guidelines and if they were based on research financed by the Chilean National Commission for Science and Technology. Material and Methods: The references of the 82 guidelines developed for 80 diseases were reviewed, registering their number, authors, country of origin and funding source. Results: The guidelines had a total of 6,604 references. Of these, only 185 were Chilean (2.8%) and five (0.08%) originated from research financed by the National Commission for Science and Technology. Conclusions: The contribution of research funded by national agencies to the formulation of clinical guidelines is minimal.